BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lavengratinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lavengratinib\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07297875-2324@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Lavengratinib: Phase 1/2 readout est. (NCT07297875)
DESCRIPTION:Lavengratinib\, phase 1/2\, Achondroplasia.\nStudy: A Study of 
 ABSK061 to Assess Safety\, Tolerability\, Pharmacokinetics\, and Efficacy 
 in Children With Achondroplasia\nEstimated primary completion: 15 December
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/lavengratinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0729
 7875
URL:https://assetmemo.bio/drug/lavengratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632262-2324@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Lavengratinib: Phase 2 readout est. (NCT06632262)
DESCRIPTION:Lavengratinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase 2 Clinical Study of ABSK061 and ABSK043\nEstimated primary completi
 on: 30 November 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /lavengratinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06632262
URL:https://assetmemo.bio/drug/lavengratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
